Search clinical trials for: Dasiglucagon

Total 20 results

Zealand Pharma

Completed

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

United States
Zealand Pharma

Recruiting

A Study to Inv. Safety,Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children<6 Years With T1D

Hypoglycemia

United States
Zealand Pharma

Completed

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

Hypoglycemia

Germany
Filip Krag Knop
Zealand Pharma

Active, not recruiting

Treatment of Post-bariatric Hypoglycaemia (SHERRY)

Hyperinsulinemic Hypoglycemia | Postprandial Hypoglycemia

Denmark
Zealand Pharma

Withdrawn

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Glucose Metabolism Disorders | Hypoglycemia
University Hospital, Gentofte, Copenhagen

Completed

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

Hyperinsulinemic Hypoglycemia | Postprandial Hypoglycemia

Denmark
Zealand Pharma

Completed

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Hypoglycemia | Diabetes Mellitus, Type 1

Canada, United States, Austria, Germany
Zealand Pharma

Completed

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

Hypoglycemia

United States, Germany, Slovenia
Zealand Pharma

Completed

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Steno Diabetes Center Copenhagen

Completed

Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

Denmark
Zealand Pharma

Active, not recruiting

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Zealand Pharma

Completed

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

Canada
Zealand Pharma

Completed

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Israel, Germany
Steno Diabetes Center Copenhagen

Completed

Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

Denmark
Zealand Pharma

Completed

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Diabetes Mellitus Type 1

Germany
Inreda Diabetic B.V.

Withdrawn

A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System (STABLE-1)

Diabetes Mellitus, Type 1

Netherlands
Massachusetts General Hospital
Zealand Pharma; Beta Bionics, Inc.

Completed

The Bihormonal iLet Bionic Pancreas Feasibility Study

Type 1 Diabetes Mellitus

United States
Zealand Pharma
Massachusetts General Hospital; Beta Bionics, Inc.

Completed

Feasibility Trial Testing the Bionic Pancreas With ZP4207 (dasiglucagon)

Diabetes Mellitus, Type 1

United States
Zealand Pharma
SynteractHCR

Completed

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Hypoglycemia | Diabetes Mellitus, Type 1

United States, Austria, Canada, Germany
Insel Gruppe AG, University Hospital Bern

Withdrawn

Micro Glucagon During Exercise in Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

Switzerland

3

Subscribe